Abstract: The present invention relates to monitoring of oxidative metabolism and is, particularly, directed to a method for estimation of the lipid peroxide load or the consequent inflammatory state of a subject by measuring the concentration of the subject's oxidized HDL (high density lipoprotein) lipids. In addition, the invention is also directed to methods for the elimination of lipid peroxidation products, and attenuation of the resulting oxidative stress and inflammatory state in the human body by increasing the lipid peroxide transporting capacity of HDL.

Abstract: The present invention relates to monitoring of lipid metabolism and is, particularly, directed to a test for estimating the individual susceptibility of a subject to the effect of oxidized dietary lipids. A high calorie and high fat meal were given to subjects and postprandial levels of oxidized low-density lipoproteins (LDL) were measured in the plasma of the subjects, indicating susceptibility to atherosclerotic events and insulin resistance. Food were also analysed for peroxide lipid content indicating LDL oxidizing potential of said foodstuff in a subject after consumption.

Abstract: The present invention relates to monitoring of oxidative metabolism and is, particularly, directed to a method for the estimation of lipid peroxide load or the consequent inflammatory state of a subject by measuring the concentration of oxidized HDL lipids of said subject. In addition, the invention is also directed to methods for elimination of lipid peroxidation products, and attenuation of the resulting oxidative stress and inflammatory state in human body, by increasing the lipid peroxide transporting capacity of HDL.

Abstract: A topical formulation which includes a lignan or lignan ester in a dermatologically acceptable vehicle. The formulation can be either a cosmetic formulation or a pharmaceutical formulation.

Abstract: The invention relates to a method of inhibiting myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan, where said lignan is enterolactone. The invention is further directed to a method inhibiting myeloperoxidase activity or oxidative burst of macrophages in an individual by administering to the individual an effective amount of a lignan where said lignan is enterolactone or hydroxymatairesinol or a mixture. Finally, the invention is directed to a method of inhibiting oxidative burst or myeloperoxidase activity in neutrophils in an individual by administering to the individual an effective amount of a lignan which is hydroxymatairesinol.

Abstract: A food product containing an effective amount of an active agent which is hydroxymatairesinol, a geometric isomer or stereoisomer thereof, or an acceptable salt thereof, or a mixture thereof, where the food product is selected from the group consisting of a nutritional supplement and a nutrient. The food product can increase the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on the administration of hydroxymatairesinol to the person.

Abstract: A topical formulation which includes a lignan or lignan ester in a dermatologically acceptable vehicle. The formulation can be either a cosmetic formulation or a pharmaceutical formulation.

Abstract: Kits are provided for use in the screening of the risk for, the diagnosis, management and research of atherosclerosis and coronary heart disease comprising means for isolating LDL from a serum or plasma sample for the preparation of a LDL fraction, and means for separating the lipids from the LDL fraction to obtain a lipid fraction. The kit can further include a means for use in the determination of the level of conjugated dienes (LDL-BDC) in the lipid fraction. The invention also relates to a kit for in the above mentioned purpose including means for isolating LDL from a serum or plasma sample for the preparation of a LDL fraction, and means for use in the determination of the antioxidant potential of LDL in the sample.

Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Abstract: This invention relates to a method of inhibiting the overactivity of phagocytes or lymphocytes in an individual by administering to said individual an effective amount of a lignan, wherein

Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

Abstract: A new use of halogenated triphenylethylene derivatives for lowering levels of serum lipid peroxides and for the prevention or treatment of oxidative tissue damage induced by lipid peroxidation is disclosed. The new use includes the prevention or treatment of artherosclerosis, ischemic injury, psoriasis, inflammatory diseases, such as inflammatory bowel disease, or cardiovascular disorders, such as coronary heart disease, cardiac ischemic injury and post-ischemic cardiac arrhythmias, or the treatment of AIDS.

Abstract: A new use of halogenated triphenylethylene derivatives for lowering levels of serum lipid perioxides and for the prevention or treatment of oxidative tissue damage induced by lipid peroxidation is disclosed. The new use includes the prevention or treatment of atherosclerosis, ischemic injury, psoriasis, inflammatory diseases, such as inflammatory bowel disease, or cardiovascular disorders, such as coronary heart disease, cardiac ischemic injury and post-ischemic cardiac arrhythmias, or the treatment of AIDS.

Abstract: A method for the determination of the oxidizability of low density lipoproteins (LDL) in a serum or plasma sample from a mammal, which method comprisesisolating the LDL from the serum or plasma sample for the preparation of a LDL fraction,separating the lipids from the LDL fraction to obtain a lipid fraction therefrom,determining the baseline level of conjugated dienes (BDC) in the lipid fraction.